Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARNA NASDAQ:AUPH NASDAQ:HRTX NASDAQ:RARX NASDAQ:THOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARNAArena Pharmaceuticals$99.99$97.65$45.50▼$100.00$6.17B0.551.56 million shs107 shsAUPHAurinia Pharmaceuticals$9.07+2.5%$8.12$5.20▼$10.67$1.23B1.161.40 million shs1.95 million shsHRTXHeron Therapeutics$2.00-1.0%$2.03$1.04▼$3.73$305.13M1.182.14 million shs861,287 shsRARXRa Pharmaceuticals$47.99$47.99$19.64▼$48.02$2.27B1.051.16 million shs30,200 shsTHORSynthorx$67.99$67.99$11.05▼$71.90$2.20BN/A474,507 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARNAArena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AUPHAurinia Pharmaceuticals-1.56%+5.48%+8.72%+14.02%+52.59%HRTXHeron Therapeutics-0.98%-9.42%-0.49%+9.78%-44.96%RARXRa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%THORSynthorx0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARNAArena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAUPHAurinia Pharmaceuticals3.1754 of 5 stars3.52.00.00.03.40.81.9HRTXHeron Therapeutics3.5539 of 5 stars3.50.00.04.21.61.70.6RARXRa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARNAArena Pharmaceuticals 0.00N/AN/AN/AAUPHAurinia Pharmaceuticals 3.00Buy$11.5026.79% UpsideHRTXHeron Therapeutics 3.00Buy$5.00150.00% UpsideRARXRa Pharmaceuticals 0.00N/AN/AN/ATHORSynthorx 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HRTX, RARX, THOR, AUPH, and ARNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARNAArena Pharmaceuticals$50K123,305.67N/AN/A$10.94 per share9.14AUPHAurinia Pharmaceuticals$235.13M5.21$0.31 per share29.15$2.68 per share3.38HRTXHeron Therapeutics$148.52M2.05N/AN/A($0.22) per share-9.09RARXRa Pharmaceuticals$3M757.11N/AN/A$5.56 per share8.63THORSynthorxN/AN/AN/AN/A$6.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARNAArena Pharmaceuticals-$616.43M-$10.13N/AN/AN/AN/A-69.83%-62.35%N/AAUPHAurinia Pharmaceuticals$5.75M$0.2832.3916.20N/A16.11%14.27%9.93%7/30/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)RARXRa Pharmaceuticals-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/ATHORSynthorx-$56.61M-$6.59N/AN/AN/AN/A-26.09%-24.62%N/ALatest HRTX, RARX, THOR, AUPH, and ARNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AUPHAurinia Pharmaceuticals$0.18N/AN/AN/A$64.27 millionN/A8/5/2025Q2 2025HRTXHeron Therapeutics-$0.01N/AN/AN/A$38.08 millionN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARNAArena PharmaceuticalsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARNAArena Pharmaceuticals0.058.598.59AUPHAurinia Pharmaceuticals0.165.935.26HRTXHeron TherapeuticsN/A2.401.76RARXRa Pharmaceuticals0.0114.7814.79THORSynthorxN/A18.8718.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARNAArena Pharmaceuticals83.77%AUPHAurinia Pharmaceuticals36.83%HRTXHeron Therapeutics80.01%RARXRa PharmaceuticalsN/ATHORSynthorx66.12%Insider OwnershipCompanyInsider OwnershipARNAArena Pharmaceuticals2.41%AUPHAurinia Pharmaceuticals12.20%HRTXHeron Therapeutics5.86%RARXRa Pharmaceuticals4.30%THORSynthorx53.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARNAArena Pharmaceuticals44861.66 million60.17 millionOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableHRTXHeron Therapeutics300152.56 million143.62 millionOptionableRARXRa Pharmaceuticals7247.33 millionN/AOptionableTHORSynthorx4832.34 millionN/ANot OptionableHRTX, RARX, THOR, AUPH, and ARNA HeadlinesRecent News About These CompaniesSanofi axes diabetes R&D, focuses on 'transformative' therapiesNovember 17, 2024 | pharmaphorum.comPDesign Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | seekingalpha.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | insidermonkey.comEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial OfficerMarch 14, 2024 | finance.yahoo.comDupixent Redux? Synthekine, Sanofi Partner on Cytokine TherapiesJanuary 29, 2024 | genengnews.comGSanofi pays Synthekine $40M to join preclinical push against vexing inflammatory targetJanuary 29, 2024 | fiercebiotech.comFEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of DirectorsDecember 19, 2023 | finance.yahoo.com‘We Have a Whole Ecosystem’: Barbara Borden Reflects on Blockbuster Horizon-Amgen Deal and Life Sciences Deals to ComeNovember 2, 2023 | law.comLPegenzileukin by Sanofi for Non-Small Cell Lung Cancer: Likelihood of ApprovalOctober 27, 2023 | pharmaceutical-technology.comPPegenzileukin by Sanofi for Squamous Cell Carcinoma: Likelihood of ApprovalJune 10, 2023 | pharmaceutical-technology.comPPegenzileukin by Sanofi for Diffuse Large B-Cell Lymphoma: Likelihood of ApprovalJune 10, 2023 | pharmaceutical-technology.comPMerck's $11B Prometheus Acquisition Brings IBD Drug & Precision ... - MedCity NewsApril 17, 2023 | news.google.comNCapstan Therapeutics Appoints Justin Thacker as Chief Financial ... - Business WireMarch 22, 2023 | news.google.comNCapstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel - Yahoo FinanceMarch 22, 2023 | news.google.comNSanofi Goes All In For Type 1 Diabetes With Provention Buy - ScripMarch 13, 2023 | news.google.comNPegenzileukin by Sanofi for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of ApprovalMarch 3, 2023 | pharmaceutical-technology.comPBridge holds firm despite placebo beating drug in midphase ... - FierceBiotechFebruary 21, 2023 | news.google.comNBiosimilar Interleukins Global Market Report 2023February 16, 2023 | uk.finance.yahoo.comReed Reaches End Of The Road As Sanofi R&D Chief - ScripFebruary 13, 2023 | news.google.comN'Robust Ecosystem' Gives Strength to San Diego's Life Science Sector - San Diego Business JournalFebruary 6, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend5 Hot Stocks With Summer Buybacks You Can Cash In OnBy Thomas Hughes | July 10, 2025View 5 Hot Stocks With Summer Buybacks You Can Cash In OnYield Generators: 3 Stocks Enhancing Shareholder ValueBy Leo Miller | July 9, 2025View Yield Generators: 3 Stocks Enhancing Shareholder ValueThese 2025 Outperformers Just Unlocked Buyback FuelBy Leo Miller | July 16, 2025View These 2025 Outperformers Just Unlocked Buyback FuelHRTX, RARX, THOR, AUPH, and ARNA Company DescriptionsArena Pharmaceuticals NASDAQ:ARNAArena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.Aurinia Pharmaceuticals NASDAQ:AUPH$9.07 +0.22 (+2.49%) Closing price 04:00 PM EasternExtended Trading$8.94 -0.13 (-1.38%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Heron Therapeutics NASDAQ:HRTX$2.00 -0.02 (-0.99%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.00 (+0.25%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Ra Pharmaceuticals NASDAQ:RARXRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.Synthorx NASDAQ:THORSynthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
